How to use Prolaris with a biopsy sample
Prolaris testing should be done following an affirmative biopsy and prostate cancer diagnosis. Prolaris testing on the biopsy tissue can help determine, in addition to traditional clinical features like Gleason and PSA, the aggressiveness of cancer to measure the cancer’s proliferation. A Prolaris score™ will:
- Help differentiate patients with similar AUA (D’Amico) risk profiles
- Help better assess the risk of prostate cancer specific mortality
- Help individualize prostate cancer treatment decisions for your patients
Prolaris has been proven to predict disease specific mortality in prostate cancer patients following needle biopsy. In a study of men with conservatively managed, localized prostate cancer, with an end point of disease specific mortality, Prolaris was predictive of disease aggressiveness
Using Prolaris with post-prostatectomy patients
Prolaris testing is particularly well-suited for post-prostatectomy patients to better estimate the risk of biochemical recurrence (BCR). Managing patients before and after BCR is a complex issue.
“The clinical course of patients with BCR is highly variable. Some experience rapid clinical progression (CP) to metastases. For others, a rising PSA may pose no threat to longevity… . Improved methods for risk stratification allow for identification of patients who require treatment. Furthermore, these methods aid in determination of the pattern of disease recurrence, thereby guiding treatment modality…. For patients with BCR, an assessment of the risk that recurrent disease poses to longevity or quality of life should be made. Many patients have indolent disease that grows slowly and requires no treatment, but some will have rapid progression to metastasis.” – European Association of Urology, 2007
Prolaris is a risk stratification tool, designed to predict an individual’s relative risk of BCR within ten years. It can enable you to better define a treatment or monitoring strategy for your patients after surgery, enhancing their quality of life without jeopardizing their life expectancy.
Prolaris can identify patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and benefit from closer monitoring or additional therapy.
Prolaris has been proven to predict prostate cancer-specific disease progression in two independent clinical studies after prostatectomy. You can read these publications via the links below: